AbstractThis study follows the expression of CReMM, a new CHD family member, in osteoprogenitors. CReMM expression was analyzed in primary cultured mesnchymal cells from rat and human. Analysis in ex vivo cultured marrow stromal cells (MSC) from rats revealed higher level of CReMM in cells from young (3 months), when compared to cells from old (15 months) rats. CReMM level was higher in human MSC then in mature trabecular bone cells (TBC). Within the MSC population, osteogenic clones showed higher levels of CReMM then non‐osteogenic ones. We used bone marrow derived osteogenic cell line (MBA‐15) to elaborate on the regulation of CReMM expression in correlation with cell proliferation and co‐expression with alkaline phosphatase (ALK). CReMM is highly expressed in proliferating cells and is inversely related to expression of ALK. MBA‐15 cells were challenged with dexamethasone (Dex) or 17β‐estradiol and quantification of CReMM at the protein (ELISA) and mRNA (RT‐PCR) levels had shown that Dex upregulated CReMM levels. Since CReMM is regulated by Dex, we analyzed the interaction of CReMM with the glucocorticoid receptor (GR), which mediates Dex action. Co‐immunopercipitation (Co‐IP) demonstrated an association between CReMM and GR. In summary, CReMM is a CHD protein expressed by osteoprogenitors, and we suggest it plays a role in mediating transcriptional response to hormones that coordinate osteoblast function. J. Cell. Physiol. © 2006 Wiley‐Liss, Inc.